Welcome to the annual general meeting of Agrokultura AB

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 15, 2014 at 9:45 AM

[b]Welcome to the annual general meeting of Agrokultura AB (publ) on 15 May 2014[/b]

The board of directors of Agrokultura AB (publ) has today resolved to issue a notice to attend the annual general meeting at 10.00 a.m. on 15 May 2014 at Advokatfirman Delphi’s premises on Regeringsgatan 30-32 in Stockholm, Sweden. Registration for the meeting commences at 09.30 a.m. Right to participate Shareholders wishing to participate at the meeting must be entered as owners in the shareholders’ register, kept by Euroclear Sweden AB (the Swedish Central Securities Depository & Clearing Organisation), on the record day which is 9 May 2014; and notify the company of their attendance and any assistant no later than 9 May 2014. Notification can be made via letter to Agrokultura AB, ”Årsstämma”, Artillerigatan 6, SE-114 51 Stockholm, Sweden or by e-mail to info@agrokultura.com. Notification shall include full name, personal identification number or corporate registration number, address and daytime telephone number and, where appropriate, information about representative, proxy and assistants. The number of assistants may not be more than two. Proposed agenda for the annual general meeting 1. Opening of the meeting 2. Election of chairman of the meeting 3. Preparation and approval of the voting list 4. Approval of the agenda 5. Election of one or two persons to attest the minutes 6. Determination whether the meeting has been duly convened 7. Presentation by the managing director 8. Submission and presentation of the annual report and auditor´s report as well as of the consolidated accounts and the auditor’s report for the group 9. Resolutions regarding a) approval of the profit and loss account and the balance sheet as well as of the consolidated profit and loss account and the consolidated balance sheet b) allocation of the company’s financial result in accordance with the adopted balance sheet, and c) discharge from liability for the members of the board of directors and the managing director 10. Determination of the number of ordinary members and, if applicable, deputy members of the board of directors 11. Determination of the fees payable to the board of directors and the auditors 12. Election of ordinary members and, if applicable, deputy members and chairman of the board of directors as well as of auditor and, if applicable, deputy auditor 13. Resolution on changes to the articles of association 14. Resolution regarding issue authorisation 15. Closing of the meeting Other See complete notice to attend in the attached pdf-document. The notice will also be published on the company’s website www.agrokultura.com under section “Investor Relations” and be announced in the Swedish Official Gazette on 17 April 2014. A notice that summons have been made will be announced in Svenska Dagbladet on 17 April 2014. This press release contains information which the company is to disclose pursuant to the Financial Instruments Trading Act (1991:980) and/or the Securities Market Act (2007:528). This information was sent for publishing at 3:30 PM (CET) on Tuesday 15 April 2014. For additional information, please contact: Stephen Pickup, Group Managing Director, tel: +44 782 529 4352 Kristian Shaw, Group CFO, tel: +44 782 529 4356 About Agrokultura AB (publ) Agrokultura invests in farmland and produces agricultural commodities in Russia and Ukraine. The Group aims to generate an attractive return on invested capital by optimally utilizing its agricultural land bank through crop production, livestock and related operations. Shares in Agrokultura are listed in Sweden on the Nasdaq OMX First North exchange under the ticker AGRA and the Group’s Certified Adviser is Remium Nordic AB. For more information, please visit our website www.agrokultura.com.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

LG's ASIL D Certification: A Game Changer in Autos

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...